The financial managers of Worldwide Healthcare Trust are housed in a skyscraper in Midtown Manhattan. The investment team at OrbiMed Capital has more advanced medical and scientific degrees than the majority of hospital research departments, and the company has offices in twelve different countries, including New York, San Francisco, London, Hong Kong, and Shanghai. The company oversees about $20 billion in healthcare assets, and since April 1995, its UK-listed investment trust has operated with essentially the same approach. It’s a long time to concentrate on just one area. The concentration appears to have been warranted, as seen by the 30-year NAV total return of over 4,200%.
As of April 2026, the share price is in the mid-300s pence, trading at a discount of about 7 to 9 percent to an estimated NAV of about 375p. The 52-week range of 272.5p to 397.0p depicts a turbulent 12 months: a severe loss followed by a sharp recovery, driven by reasons largely related to the political climate in Washington rather than the underlying quality of the companies in the portfolio. The trust reached its lowest point of the year as investors realized the implications of Donald Trump’s reelection and Robert F. Kennedy Jr.’s selection as Health Secretary for government healthcare spending, pharmaceutical prices, and vaccine policy. There was a real sell-off. After markets calibrated, so was the recovery.
Important Information
| Field | Details |
|---|---|
| Trust | Worldwide Healthcare Trust PLC (LSE: WWH) — launched April 1995; previously known as Finsbury Worldwide Pharmaceutical Trust; listed on the London Stock Exchange; AIC sector: Specialist Biotech & Healthcare |
| Share Price (April 2026) | Approximately 325–346p; 52-week range 272.5p–397.0p; estimated NAV approximately 375p; discount to NAV approximately 7–9%; market capitalisation approximately £1.2–1.5 billion; dividend yield approximately 0.7% |
| Manager | OrbiMed Capital LLC — New York-based specialist healthcare investment firm; approximately $20 billion assets under management; 12 offices worldwide including New York, San Francisco, London, Hong Kong, Shanghai and Mumbai; co-managers Sven Borho and Trevor Polischuk |
| H1 FY2026 Performance (to 30 September 2025) | NAV total return +5.0%; share price total return +10.9%; benchmark (MSCI World Health Care, sterling adjusted) returned -5.3% — making this the trust’s best six-month relative performance in the past decade |
| Long-Term Record | Since April 1995 launch to September 2025: average annual NAV total return +13.4% versus benchmark +10.9%; 30-year cumulative NAV total return more than 4,200%; 30-year cumulative share price total return more than 3,500% |
| FY2025 (year to 31 March 2025) | Disappointing year: NAV total return -10.3% versus benchmark -3.2%; share price fell -11.2%; driven by biotech underperformance, RFK Jr appointment as US Health Secretary, drug pricing concerns, and political uncertainty around healthcare sector |
| Key Portfolio Feature | Proprietary M&A swap basket — derivative product managed by OrbiMed consisting of 60 biotech companies at end-September 2025 (up from 20 at end-September 2024) believed to be likely acquisition targets; since inception in April 2022 the basket appreciated 72.9%, far ahead of the XBI biotech index (+26.8%) |
| Macro Headwinds | Trump administration pharmaceutical tariff proposals; RFK Jr. vaccine scepticism as Health Secretary; Medicare drug price negotiations commencing 2026; China market exposure; political uncertainty around US healthcare policy |
The half-year results up to September 30, 2025, were the kind of figures that necessitate a second look. In six months, the NAV total return was plus 5.0%. A total return on share price of + 10.9%. During the same time period, the benchmark, MSCI World Health Care in sterling, saw a negative return of 5.3%.
Edison Investment Research recognized the trust’s outperformance margin of over 16 percentage points in a single half-year as its highest six-month relative performance in the previous ten years. The biotech holdings and Chinese healthcare stocks, which had been a recurring source of underperformance in the years prior, were the main drivers. As sentiment changed and certain catalysts emerged, both of these stocks underwent a forceful reversal.
A product that is uncommon in investment trust portfolios—OrbiMed’s bespoke M&A swap basket—contributes significantly to both the underperformance and recovery tale. OrbiMed’s experts have identified about sixty biotech companies as potential acquisition targets for this derivative instrument. These holdings gain when pharmaceutical companies use their funds to purchase pipeline assets, which they have been doing more quickly in advance of the Medicare medication price talks starting in 2026.
The basket has increased by 72.9% since its launch in April 2022, while the XBI biotech index has increased by 26.8%. The value of the thesis is represented by this gap, which also explains why the portfolio has occasionally moved in both directions differently from the headline biotech indices.
The FY2025 yearly results, which covered the period ending on March 31, 2025, were subpar. Compared to a benchmark fall of 3.2%, NAV dropped 10.3%. The biotech exposure that OrbiMed has consistently maintained as a source of long-term alpha—the same exposure that propelled the second half recovery—was the focus of the underperformance.
The year was defined by a record NAV high in August 2024, which was followed by a decline in the last quarter as the RFK appointment, tariff rhetoric on pharmaceutical imports, and Trump’s reelection cast a shadow over the healthcare industry that valuation fundamentals could not dispel. The discount to NAV of about 7 to 9 percent seems to provide something intriguing for investors who think the political challenges are manageable rather than structural, based on the price movement over the last 12 months.
The managers of OrbiMed have provided some specific details about their “playbook” for 2026: drug M&A is speeding up, about 30% of the biotech sector is currently trading at market caps below the cash on their balance sheets, and the trust’s innovation focus is situated in a segment of the market where the underlying biology is advancing regardless of who controls the White House. Whether the pharmaceutical tariff plans materialize or dissipate like much of the early trade war rhetoric is still up in the air. However, the 30-year record illustrates what happens when that ambiguity is eventually resolved.
